Takeda Still Hopeful On Dengue Vaccine Candidate
Company Says Loss Of EU Fast-Track Status Is 'Not Uncommon'
Takeda says loss of accelerated assessment status at EMA for marketing authorization application for its dengue vaccine candidate TAK-003 “was anticipated as a potential outcome.”
